PMC:4114101 / 146-641 JSONTXT

{"project":"NEUROSES","denotations":[{"id":"T71","span":{"begin":66,"end":72},"obj":"PATO_0000461"},{"id":"T75","span":{"begin":449,"end":456},"obj":"PATO_0000392"},{"id":"T80","span":{"begin":25,"end":49},"obj":"PM4555"},{"id":"T82","span":{"begin":36,"end":49},"obj":"PM8694"},{"id":"T47","span":{"begin":79,"end":85},"obj":"PATO_0000119"},{"id":"T48","span":{"begin":112,"end":118},"obj":"PATO_0000119"},{"id":"T53","span":{"begin":36,"end":41},"obj":"PATO_0000569"},{"id":"T54","span":{"begin":267,"end":272},"obj":"PATO_0000569"},{"id":"T62","span":{"begin":36,"end":41},"obj":"PATO_0000574"},{"id":"T63","span":{"begin":267,"end":272},"obj":"PATO_0000574"}],"text":"Background\nChildren with Idiopathic Short Stature do not attain a normal adult height. The improvement of adult height with treatment with recombinant human growth hormone (rhGH), at doses of 0.16 to 0.28 mg/kg/week is modest, usually less that 4 cm, and they remain short as adults. The benefit obtained seems dose dependent and benefits of 7.0 to 8.0 cm have been reported with higher doses of 0.32 to 0.4 mg/kg/week, but the number of studies is limited. The topic has remained controversial."}